News
AADI
2.340
-1.27%
-0.030
Weekly Report: what happened at AADI last week (0318-0322)?
Weekly Report · 3d ago
Aadi Bioscience (AADI) Receives a Hold from H.C. Wainwright
TipRanks · 03/18 10:15
Weekly Report: what happened at AADI last week (0311-0315)?
Weekly Report · 03/18 10:02
Reported Sunday, Aadi Bioscience Presented New Subgroup Analysis Of Patients With Advanced Malignant PEComa Of Gynecologic Origin Treated With nab-Sirolimus At Society Of Gynecologic Oncology
Benzinga · 03/18 06:24
TD Cowen Keeps Their Buy Rating on Aadi Bioscience (AADI)
TipRanks · 03/13 16:45
Aadi Bioscience Inc reports results for the quarter ended in December - Earnings Summary
Aadi Bioscience Inc reports results for the quarter ended in December. The company reported a quarterly adjusted loss of 60 cents per share. Revenue rose 19.9% to $6.33 million from a year ago. The average analyst rating on the company's shares is "buy"
Reuters · 03/13 14:09
Aadi Bioscience, Inc. (AADI) Reports Q4 Loss, Misses Revenue Estimates
NASDAQ · 03/13 13:05
*Aadi Bioscience Cash Runway Extends to 4Q 2025 >AADI
Dow Jones · 03/13 12:04
*Aadi Bioscience 4Q Loss/Shr 60c >AADI
Dow Jones · 03/13 12:03
*Aadi Bioscience 4Q R&D Expenses $12.8M >AADI
Dow Jones · 03/13 12:03
Aadi Bioscience Q4 GAAP EPS $(0.60) Beats $(0.65) Estimate, Sales $6.33M Beat $6.29M Estimate
Aadi Bioscience (NASDAQ:AADI) reported quarterly losses of $0.60 per share. The company reported quarterly sales of $6.33 million. Aadi beat the analyst consensus estimate of $5.23 million for the same period last year.
Benzinga · 03/13 12:02
Aadi Bioscience GAAP EPS of -$0.60 beats by $0.05, revenue of $6.33M beats by $0.03M
Seeking Alpha · 03/13 12:02
*Aadi Bioscience 4Q Rev $6.3M >AADI
Dow Jones · 03/13 12:02
Press Release: Aadi Bioscience Announces -2-
IR@aadibio.com AADI BIOSCIENCE, INC. The company has a total of $1.2 billion in assets and liabilities as of December 31, 2018. The Company has no debt and no current liabilities. The company's assets are held in cash and short-term investments and other assets. The Company's liabilities include liabilities and inventory.
Dow Jones · 03/13 12:00
Earnings Scheduled For March 13, 2024
Sangamo Therapeutics is expected to report earnings for its fourth quarter. Dollar Tree is estimated to report quarterly earnings at $2.65 per share on revenue of $8.67 billion. Other companies reporting before the bell and after the bell include i-80 Gold and Optical Cable.
Benzinga · 03/13 10:15
NGM Biopharmaceuticals (NGM) Reports Q4 Loss, Lags Revenue Estimates
NASDAQ · 03/11 21:30
Aadi Bioscience Inc <AADI.OQ> expected to post a loss of 65 cents a share - Earnings Preview
Aadi Bioscience Inc expected to post a loss of 65 cents a share. The company is expected to report a 19.2% increase in quarterly revenue to $6.293 million from $5.28 million. The average analyst estimate for the company's quarterly revenue is for a rise of 19.3%.
Reuters · 03/11 12:53
Weekly Report: what happened at AADI last week (0304-0308)?
Weekly Report · 03/11 10:00
Evogene (EVGN) Reports Q4 Loss, Misses Revenue Estimates
NASDAQ · 03/07 14:20
Why Bitdeer Technologies Shares Are Trading Higher By 10%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Bitdeer Technologies Group shares jumped 10.2% to $7.45 on Monday. The company announced successful testing of its SEAL01 Bitcoin mining chip. BitFuFu Inc. Shares jumped 107% in the mid-day session. Macy's, Inc. And MGE also rose amid strength in the price of Bitcoin.
Benzinga · 03/04 18:29
More
Webull provides a variety of real-time AADI stock news. You can receive the latest news about Aadi Bioscience Inc through multiple platforms. This information may help you make smarter investment decisions.
About AADI
Aadi Bioscience, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on developing and commercializing precision therapies for cancers with alterations in the mammalian target of rapamycin (mTOR) pathway, a regulator of cell growth and cancer progression. Its lead drug product, FYARRO, is an mTOR inhibitor indicated for the treatment of adult patients with locally advanced unresectable or metastatic malignant perivascular epithelioid cell tumor (PEComa). FYARRO is a form of sirolimus bound to albumin. Sirolimus is a potent inhibitor of the mTOR biological pathway and inhibits downstream signaling from mTOR, which can promote tumor growth. FYARRO is composed of nanoparticles of sirolimus bound to human albumin with an average size less than 100 nanometers. It has also initiated a tumor-agnostic Phase II study (PRECISION 1) of FYARRO in patients with Tuberous Sclerosis Complex 1 and 2 (TSC1 and TSC2) alterations.